Phase 1/2 Randomized Trial Combination of Ruxolitinib and Peg-interferon Alpha-2a in Patients With Primary Myelofibrosis Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis
Phase of Trial: Phase I/II
Latest Information Update: 03 Apr 2018
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ruxolitinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions; Therapeutic Use
- 27 Mar 2018 Planned End Date changed from 1 Oct 2018 to 1 Dec 2018.
- 07 Dec 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated